Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 3
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Lercanidipine 10mg
Lercanidipine10mg /Valsartan 80mg
Lercanidipine 10mg /Valsartan 160mg
Lercanidipin 10mg Placebo
Lercanidipine10mg /Valsartan 80mg Placebo
Lercanidipine 10mg /Valsartan 160mg Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Patients aged ≥ 20 to ≤75 years old
- Patient with essential hypertension
Exclusion Criteria:
- When the BP level measured at screening was sitDBP>120 mmHg or sitSBP >180 mmHg
- Patient with difference in repeatedly measured blood pressures from the selected arm at screening was sitSBP≥ 20mmHg or sitDBP ≥ 10mmHg
Sites / Locations
- Seoul National University Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Active Comparator
Experimental
Experimental
Arm Label
Lercanidipine 10mg
Lercanidipine10mg /Valsartan 80mg
Lercanidipine 10mg /Valsartan 160mg
Arm Description
1 Tablet of Zanidip ® 10mg + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/V160 Placebo (8wks)
1 Tablet of Zanidip ® 10mg Placebo +1 Tablet of L10/V80 + 1 Tablet of L10/V160 Placebo (8wks)
1 Tablet of Zanidip ® 10mg Placebo + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/ V160 (8wks)
Outcomes
Primary Outcome Measures
Change in mean sitDBP from week 0 to week 40
Secondary Outcome Measures
Response rate at week 4 and 8
Proportion (%) of patients with mean sitDBP<90mmHg or proportion (%) of patients with mean reduction of sitDBP ≥10mmHg from week 0
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01928628
Brief Title
Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients
Official Title
A Randomized, Multicenter, Parallel Design Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients Who Are Not Adequately Controlled on Lercanidipine 10mg Monotherapy.
Study Type
Interventional
2. Study Status
Record Verification Date
August 2013
Overall Recruitment Status
Completed
Study Start Date
May 2012 (undefined)
Primary Completion Date
April 2013 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
LG Life Sciences
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study aims to compare and assess the efficacy and the safety of the combination agent of Lercanidipine and Valsartan and monotherapy of Lercanidipine alone in patients with essential hypertension
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
449 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Lercanidipine 10mg
Arm Type
Active Comparator
Arm Description
1 Tablet of Zanidip ® 10mg + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/V160 Placebo (8wks)
Arm Title
Lercanidipine10mg /Valsartan 80mg
Arm Type
Experimental
Arm Description
1 Tablet of Zanidip ® 10mg Placebo +1 Tablet of L10/V80 + 1 Tablet of L10/V160 Placebo (8wks)
Arm Title
Lercanidipine 10mg /Valsartan 160mg
Arm Type
Experimental
Arm Description
1 Tablet of Zanidip ® 10mg Placebo + 1 Tablet of L10/V80 Placebo + 1 Tablet of L10/ V160 (8wks)
Intervention Type
Drug
Intervention Name(s)
Lercanidipine 10mg
Intervention Type
Drug
Intervention Name(s)
Lercanidipine10mg /Valsartan 80mg
Intervention Type
Drug
Intervention Name(s)
Lercanidipine 10mg /Valsartan 160mg
Intervention Type
Drug
Intervention Name(s)
Lercanidipin 10mg Placebo
Intervention Type
Drug
Intervention Name(s)
Lercanidipine10mg /Valsartan 80mg Placebo
Intervention Type
Drug
Intervention Name(s)
Lercanidipine 10mg /Valsartan 160mg Placebo
Primary Outcome Measure Information:
Title
Change in mean sitDBP from week 0 to week 40
Time Frame
40 weeks
Secondary Outcome Measure Information:
Title
Response rate at week 4 and 8
Description
Proportion (%) of patients with mean sitDBP<90mmHg or proportion (%) of patients with mean reduction of sitDBP ≥10mmHg from week 0
Time Frame
4 weeks and 8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients aged ≥ 20 to ≤75 years old
Patient with essential hypertension
Exclusion Criteria:
When the BP level measured at screening was sitDBP>120 mmHg or sitSBP >180 mmHg
Patient with difference in repeatedly measured blood pressures from the selected arm at screening was sitSBP≥ 20mmHg or sitDBP ≥ 10mmHg
Facility Information:
Facility Name
Seoul National University Hospital
City
Seoul
Country
Korea, Republic of
12. IPD Sharing Statement
Citations:
PubMed Identifier
26164786
Citation
Na SH, Lee HY, Hong Baek S, Jeon HK, Kang JH, Kim YN, Park CG, Ryu JK, Rhee MY, Kim MH, Hong TJ, Choi DJ, Cho SW, Cha DH, Jeon ES, Kim JJ, Shin JH, Park SH, Lee SH, John SH, Shin ES, Kim NH, Lee SY, Kwan J, Jeong MH, Kim SW, Jeong JO, Kim DW, Lee NH, Park WJ, Ahn JC, Won KH, Uk Lee S, Cho JH, Kim SK, Ahn T, Hong S, Yoo SY, Kim SY, Kim BS, Juhn JH, Kim SY, Lee YJ, Oh BH. Evaluation of the Efficacy and Safety of the Lercanidipine/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial. Clin Ther. 2015 Aug;37(8):1726-39. doi: 10.1016/j.clinthera.2015.05.512. Epub 2015 Jul 8.
Results Reference
derived
Learn more about this trial
Phase III Clinical Study to Evaluate the Efficacy and Safety of the Combination of Lercanidipine/Valsartan in Hypertensive Patients
We'll reach out to this number within 24 hrs